Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 459846 | https://doi.org/10.1155/2015/459846

Jerônimo Aparecido Ribeiro-Junior, Marcelo Franchin, Miriam Elias Cavallini, Carina Denny, Severino Matias de Alencar, Masaharu Ikegaki, Pedro Luiz Rosalen, "Gastroprotective Effect of Geopropolis from Melipona scutellaris Is Dependent on Production of Nitric Oxide and Prostaglandin", Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 459846, 5 pages, 2015. https://doi.org/10.1155/2015/459846

Gastroprotective Effect of Geopropolis from Melipona scutellaris Is Dependent on Production of Nitric Oxide and Prostaglandin

Academic Editor: Yoshiji Ohta
Received15 Dec 2014
Revised18 Mar 2015
Accepted18 Mar 2015
Published08 Apr 2015

Abstract

The aim of this study was to evaluate the gastroprotective activity of ethanolic extract of geopropolis (EEGP) from Melipona scutellaris and to investigate the possible mechanisms of action. The gastroprotective activity of the EEGP was evaluated using model ulcer induced by ethanol. To elucidate the possible mechanisms of action, we investigated the involvement of the nonprotein sulfhydryl (NP-SH) groups, nitric oxide and prostaglandins. In addition, the antisecretory activity of EEGP was also evaluated by pylorus ligated model. The EEGP orally administrated (300 mg/kg) reduced the ulcerative lesions induced by the ethanol (). Regarding the mechanism of action, the prior administration of nitric oxide and prostaglandins antagonists suppressed the activity of gastroprotective EEGP (). On the other hand the gastroprotective activity of EEGP was kept in the group pretreated with the antagonist of the NP-SH groups; furthermore the antisecretory activity was not significant (). These results support the alternative medicine use of geopropolis as gastroprotective and the activities observed show to be related to nitric oxide and prostaglandins production.

1. Introduction

Peptic ulcers are the imbalance between the aggressive agents (Helicobacter pylori and anti-inflammatory drugs, among others) and the protective agents (prostaglandins and nitric oxide, among others) [1, 2]. Despite the widespread use of different classes of monodrugs for the treatment of different types of ulcers, a large part of the world’s population still benefits from the use of natural products [3].

The propolis is a nontoxic natural product, collected by bees from different plant parts [4]. Propolis has increased in popularity as an alternative medicine or dietary supplement, for improving health and preventing disease in various parts of the world [5]. Among the several biological activities of propolis reported in the literature antimicrobial, anti-inflammatory, anticancer, laxative, and antiulcer can be found [610].

The geopropolis, a mixture of resin, wax, and soil, is a propolis collected by a native stingless bee of the Meliponini tribe [11, 12] and also widely used in folk medicine for various therapeutic purposes [5].

The geopropolis from Melipona scutellaris bee species, popularly known as “uruçu” and found in northeastern Brazil, has been the focus of our research. Studies have shown that geopropolis has antinociceptive and anti-inflammatory properties, besides antimicrobial activity against different types of bacteria. In addition, studies on the chemical profile of geopropolis revealed absence of flavonoid and phenolic acids commonly found in propolis from Apis mellifera and presence of benzophenones [1316].

Therefore, in order to aggregate scientific value to the geopropolis, this study aims at evaluating the gastroprotective activity of the ethanolic extract of geopropolis (EEGP) from Melipona scutellaris and at investigating the possible mechanisms of action.

2. Material and Methods

2.1. Obtaining the EEGP

The geopropolis samples were collected on municipality of Entre Rios (11°57′ S, 38°05′ W), state of Bahia, northeast of Brazil. The geopropolis samples (100 g) were extracted in 80% ethanol in water (w/v) at a 1/7 dilution rate at 70°C for 30 min, followed by filtration, thereby obtaining the EEGP. The same process was repeated twice. At the end, the EEGP was concentrated in a rotary evaporator at 40°C [13]. The EEGP dissolution was carried out in PBS 1 mM. The EEGP was administered to the animals by pathway oral (p.o.).

2.2. Animals

Male Wistar rats, SPF (specific-pathogen-free), weighing 200–250 g were provided by CEMIB/UNICAMP (Multidisciplinary Center for Biological Research, SP, Brazil) and kept in controlled temperature chambers (20 ± 2°C) in light-dark 12 hours cycles, relative humidity of 40 and 60%, with filtered water ad libitum. The animals fasted for 24 hours before the experiments. The procedures described were reviewed and approved by the local Animal Ethics Committee (CEUA Unicamp process number 2560-1).

2.3. Drugs and Reagents

The drugs were purchased from Sigma Chemical Co. St. Louis, MO, USA (N-ethylmaleimide, omeprazole, Nω-nitro-L-arginine methyl ester hydrochloride, and ethanol), MP Biomedicals (indomethacin), and Merck (organic solvents).

2.4. Gastric Lesion Induced by Ethanol

The rats were pretreated with EEGP at dose of 100, 200, or 300 mg/kg (p.o.). The positive control group received omeprazole 30 mg/kg (p.o.), and the negative control group received dissolving vehicle of EEGP (p.o.). One hour after the treatments, 1 mL of absolute ethanol was administered by p.o, and, one hour later, the animals were killed by anesthesia overload, and the stomach was removed and opened along the greater curvature [17]. The ulcerative lesions from each animal were calculated according to the Gamberini et al. [18] method, as described below.

2.5. Role of the Nonprotein Sulfhydryl (NP-SH) Groups on Gastroprotection Effect of the EEGP

The rats were pretreated with inhibitor of the NP-SH groups (N-ethylmaleimide 10 mg/kg, s.c.), 30 min prior to the treatment with EEGP (300 mg/kg) by p.o. [19]. The negative control group received dissolution vehicle of EEGP (p.o.). One hour after the treatments, 1 mL of absolute ethanol was administered by p.o., and, one hour later, the animals were killed by anesthesia overload, and the stomach was removed and opened along the greater curvature. The ulcerative lesions from each animal were calculated according to the Gamberini et al. [18] method.

2.6. Role of the Nitric Oxide on Gastroprotective Effect of the EEGP

The rats were pretreated with inhibitor from the nitric oxide synthase (L-NAME 5 mg/kg) by intraperitoneal (i.p.) administration, 30 min prior to the treatment with EEGP (300 mg/kg, p.o.). The negative control group received dissolution vehicle of EEGP (p.o.). One hour after the treatments, 1 mL of absolute ethanol was administered by p.o., and, one hour later, the animals were killed by anesthesia overload, and the stomach was removed and opened along the greater curvature [19]. The ulcerative lesions from each animal were calculated according to the Gamberini et al. [18] method.

2.7. Role of Prostaglandins on Gastroprotective Effect of the EEGP

The rats were pretreated with the cyclooxygenase inhibitor (indomethacin 5 mg/kg, i.p.), 30 min before the EEGP treatment (300 mg/kg, p.o.). The negative control group received dissolution vehicle of EEGP (p.o.). One hour after the treatments, 1 mL of absolute ethanol was administered by p.o., and, one hour later, the animals were killed by anesthesia overload, and the stomach was removed and opened along the greater curvature [19]. The ulcerative lesions from each animal were calculated according to the Gamberini et al. [18] method.

2.8. Evaluation of the Antisecretory Activity

The animals were anesthetized, their abdomen was dissected, and the pylorus was connected. Immediately after this procedure, the EEGP 300 mg/kg, cimetidine 100 mg/kg, or dissolution vehicle of EEGP (negative control) was administered by p.o. to the respective group of animals. The abdomens were sutured and, four hours later, the animals were killed. The stomachs were removed and the gastric content was collected and centrifuged. The volume and the pH of the gastric juice were measured [20].

2.9. Statistical Analysis

Data were expressed as means ± standard error of the mean (SEM) and statistical comparison between groups was made utilizing analysis of variance (ANOVA) followed by test of Dunnett or Tukey. Significance was accepted when .

3. Results and Discussion

This study evaluated the gastroprotective activity of EEGP from Melipona scutellaris, as well as the possible action mechanisms involved.

The geopropolis used in this work presents the same chemical composition as described in our previous publications, where absence of flavonoids and phenolic acids and presence of benzophenone were found [15, 16].

Ethanol is a potent gastric ulcer inducer agent, and it is widely applied to evaluate the gastroprotective activity of plant extracts, as well as new pharmaceutical drugs in animal models. Its effect causes an imbalance between the oxidizing and the antioxidants agents in the gastric mucosa. This imbalance causes bleeding resulting from the ruptured blood vessels [21, 22]. In the present study, we evaluated the EEGP gastroprotective activity on the ethanol-induced ulcer model (Figure 1). The EEGP (300 mg/kg) orally administrated decreased the ulcerative lesions, where an 89% reduction was detected compared to the negative control group (). Regarding the positive control group (omeprazole), there was an 85% reduction of the ulcerative lesions compared to the negative control group ().

To elucidate the possible mechanisms of action involved with the gastroprotective activity of EEGP, we investigated the participation of the NP-SH groups, nitric oxide and prostaglandins. In addition, the antisecretory activity of EEGP was also evaluated.

The NP-SH groups are protective of the gastric mucosa. In this case, the role of these mediators is associated with the free radicals blockage in the gastric mucosa [23]. Thus, in order to evaluate the EEGP association with these substances, the animals underwent a pretreatment with a blocker agent (N-ethylmaleimide 10 mg/kg) of the NP-SH groups. The results showed that the administration of the N-ethylmaleimide (Figure 2) did not suppress the gastroprotective activity of the EEGP (). Thus, suggesting that the EEGP activity is not associated with NP-SH groups.

Nitric oxide plays a vital role in gastric gastroprotection also. Among its actions are regulation of gastric secretion and gastric stimulation of mucus secretion [24, 25]. Furthermore, studies have shown that NO is able to decrease the adhesion of neutrophils to endothelial cells during the inflammatory process [26]. The pretreatment with L-NAME (inhibitor of synthesis of nitric oxide) suppressed the gastroprotective activity of EEGP (Figure 3, ). These results corroborate the study of Franchin et al. [14], where it was observed that the administration of inhibitors of nitric oxide production suppressed the anti-inflammatory activity of the EEGP. In the same study, it was found that the activity of EEGP on the inflammatory process was related to the increased production of nitric oxide (verified by quantifying nitrite), which resulted in decreased adhesion of neutrophils on endothelial cells. Therefore, the EEGP increased the gastroprotective response and reduced the ulcerogenic effect induced by ethanol in the gastric mucosa, probably by increased production of NO.

This study also evaluated the role of prostaglandins in the EEGP gastroprotective activity. Indomethacin, a nonsteroidal anti-inflammatory drug, is widely used for induction of ulcers in animal research. These drugs are known to inhibit the production of prostaglandins, including those that have protective action in the gastric tissue [27, 28]. The prostaglandins produced in the stomach exert gastroprotective activity through the stimulatory action of the gastric mucus and of bicarbonate secretion [29]. According to the results (Figure 4), it was found that the prior administration of indomethacin in ulcer model induced by ethanol reverted the EEGP gastroprotective activity (). These results suggest that the EEGP beyond develops its gastroprotective activity through modulation of nitric oxide and also acts by increasing the levels of prostaglandins present in the gastric mucosa.

Finally, we evaluated the antisecretory activity of the EEGP. Acetylcholine, histamine, and gastrin are endogenous substances responsible for the regulation of acid secretion [30]. Currently, antiulcer drugs act by blocking the acid secretion, for example, omeprazole (proton pump blockers) and cimetidine (H2 inhibitor) [31].

The model of ligature of the pylorus of the stomach in mice is widely used to study the antisecretory activity of new drugs. This fact is understandable due to the effect generated by ligation of the pylorus, which is the acids hypersecretion on stomach [20]. According to Table 1, it is observed that the volume and pH of gastric juice remained unaltered in the stomachs of animals submitted to binding the pylorus remained (), after administration of EEGP (300 mg/kg). On the other hand the positive control (cimetidine 100 mg/kg) not only decreased the gastric juice volume, but also increased the pH (). These results, therefore, suggest that the gastroprotective activity of the EEGP is not related to the regulation of gastric secretion.


TreatmentsDose (mg/kg)Volume (mL)pH

Control
Cimetidine100
EEGP300

Compared to control group (ANOVA followed by Dunnett, ).

4. Conclusion

The results of this study indicate that geopropolis exerts a gastroprotective effect in rats with ethanol-induced gastric mucosal damage. The results also suggest that the gastroprotective effect of geopropolis could be related to the gastroprotective mechanism in which nitric oxide and prostaglandins are involved.

Abbreviations

EEGP:Ethanolic extract of geopropolis
Indo:Indomethacin
NEM:N-Ethylmaleimide
NP-SH:Nonprotein sulfhydryl
OMEP:Omeprazole
L-NAME:N-nitro-L-arginine methyl ester hydrochloride.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are grateful to Mr. José Emídio Borges de Souza for providing the geopropolis samples. This research was supported by FAPESP (#2010/20214-7).

References

  1. G. Mózsik, “Gastric cytoprotection 30 years after its discovery by André Robert: a personal perspective,” Inflammopharmacology, vol. 18, no. 5, pp. 209–221, 2010. View at: Publisher Site | Google Scholar
  2. L. Laine, K. Takeuchi, and A. Tarnawski, “Gastric mucosal defense and cytoprotection: bench to bedside,” Gastroenterology, vol. 135, no. 1, pp. 41–60, 2008. View at: Publisher Site | Google Scholar
  3. M. G. Repetto and S. F. Llesuy, “Antioxidant properties of natural compounds used in popular medicine for gastric ulcers,” Brazilian Journal of Medical and Biological Research, vol. 35, no. 5, pp. 523–534, 2002. View at: Google Scholar
  4. B. B. Silva, P. L. Rosalen, J. A. Cury et al., “Chemical composition and botanical origin of red propolis, a new type of Brazilian propolis,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 313–316, 2008. View at: Publisher Site | Google Scholar
  5. S. Castaldo and F. Capasso, “Propolis, an old remedy used in modern medicine,” Fitoterapia, vol. 73, supplement 1, pp. S1–S6, 2002. View at: Publisher Site | Google Scholar
  6. M. K. Choudhari, S. A. Punekar, R. V. Ranade, and K. M. Paknikar, “Antimicrobial activity of stingless bee (Trigona sp.) propolis used in the folk medicine of Western Maharashtra, India,” Journal of Ethnopharmacology, vol. 141, no. 1, pp. 363–367, 2012. View at: Publisher Site | Google Scholar
  7. M. C. Búfalo, I. Ferreira, G. Costa et al., “Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-κB and MAPK activation in macrophages,” Journal of Ethnopharmacology, vol. 149, no. 1, pp. 84–92, 2013. View at: Publisher Site | Google Scholar
  8. R. Markiewicz-Żukowska, M. H. Borawska, A. Fiedorowicz, S. K. Naliwajko, D. Sawicka, and H. Car, “Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line,” BMC Complementary & Alternative Medicine, vol. 13, article 50, 9 pages, 2013. View at: Publisher Site | Google Scholar
  9. M. Kakino, H. Izuta, K. Tsuruma et al., “Laxative effects and mechanism of action of Brazilian green própolis,” BMC Complementary & Alternative Medicine, vol. 12, article 192, 8 pages, 2012. View at: Publisher Site | Google Scholar
  10. M. P. de Barros, J. P. B. Sousa, J. K. Bastos, and S. F. de Andrade, “Effect of Brazilian green propolis on experimental gastric ulcers in rats,” Journal of Ethnopharmacology, vol. 110, no. 3, pp. 567–571, 2007. View at: Publisher Site | Google Scholar
  11. G. Nates-Parra, “Las Abejas sin aguijón (Hymenoptera: Apidae: Meliponini) de Colômbia,” Biota Colombiana, vol. 2, pp. 233–248, 2001. View at: Google Scholar
  12. O. M. Barth, “Palynological analysis of geopropolis samples obtained from six species of Meliponinae in the Campus of the Universidade de Ribeirão Preto, Brazil,” Apiacta, vol. 41, pp. 71–85, 2006. View at: Google Scholar
  13. M. Franchin, M. G. da Cunha, C. Denny et al., “Geopropolis from Melipona scutellaris decreases the mechanical inflammatory hypernociception by inhibiting the production of IL-1β and TNF-α,” Journal of Ethnopharmacology, vol. 143, no. 2, pp. 709–715, 2012. View at: Publisher Site | Google Scholar
  14. M. Franchin, M. G. da Cunha, C. Denny et al., “Bioactive fraction of geopropolis from Melipona scutellaris decreases neutrophils migration in the inflammatory process: involvement of nitric oxide pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 907041, 9 pages, 2013. View at: Publisher Site | Google Scholar
  15. M. G. da Cunha, M. Franchin, L. C. C. Galvão et al., “Antimicrobial and antiproliferative activities of stingless bee Melipona scutellaris geopropolis,” BMC Complementary & Alternative Medicine, vol. 13, article 23, 9 pages, 2013. View at: Publisher Site | Google Scholar
  16. M. G. da Cunha, M. Franchin, L. C. C. Galvão et al., “Apolar bioactive fraction of melipona scutellaris geopropolis on Streptococcus mutans biofilm,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 256287, 7 pages, 2013. View at: Publisher Site | Google Scholar
  17. Y. Morimoto, K. Shimohara, S. Oshima, and S. Takayuki, “Effects of the new anti-ulcer agent KB-5492 on experimental gastric mucosal lesions and gastric mucosal defensive factors, as compared to those of teprenone and cimetidine,” Japanese Journal of Pharmacology, vol. 57, no. 4, pp. 495–505, 1991. View at: Publisher Site | Google Scholar
  18. M. T. Gamberini, L. A. Skorupa, C. Souccar, and A. J. Lapa, “Inhibition of gastric secretion by a water extract from Baccharistriptera Mart,” Memórias do Instituto Oswaldo Cruz, vol. 86, supplement 2, pp. 137–139, 1991. View at: Google Scholar
  19. P. C. Dias, M. A. Foglio, A. Possenti, and J. E. de Carvalho, “Antiulcerogenic activity of crude hydroalcoholic extract of Rosmarinus officinalis L.,” Journal of Ethnopharmacology, vol. 69, no. 1, pp. 57–62, 2000. View at: Publisher Site | Google Scholar
  20. H. Shay, S. A. Komarov, S. S. Fels, D. Meranze, M. Gruentein, and H. Siplet, “A simple method for the uniform production of gastric ulceration in the rat,” Gastroenterology, vol. 5, pp. 43–61, 1945. View at: Google Scholar
  21. C. H. Cho and C. W. Ogle, “The pharmacological differences and similarities between stress- and ethanol-induced gastric mucosal damage,” Life Sciences, vol. 51, no. 24, pp. 1833–1842, 1992. View at: Publisher Site | Google Scholar
  22. U. N. S. Prakash and K. Srinivasan, “Gastrointestinal protective effect of dietary spices during ethanol-induced oxidant stress in experimental rats,” Applied Physiology, Nutrition and Metabolism, vol. 35, no. 2, pp. 134–141, 2010. View at: Publisher Site | Google Scholar
  23. S. Szabo, J. S. Trier, and P. W. Frankel, “Sulfhydryl compounds may mediate gastric cytoprotection,” Science, vol. 214, no. 4517, pp. 200–202, 1981. View at: Publisher Site | Google Scholar
  24. S. Kato, M. Kitamura, R. P. Korolkiewicz, and K. Takeuchi, “Role of nitric oxide in regulation of gastric acid secretion in rats: effects of NO donors and NO synthase inhibitor,” British Journal of Pharmacology, vol. 123, no. 5, pp. 839–846, 1998. View at: Publisher Site | Google Scholar
  25. C. H. Cho, “Current roles of nitric oxide in gastrointestinal disorders,” Journal of Physiology, vol. 95, no. 1–6, pp. 253–256, 2001. View at: Publisher Site | Google Scholar
  26. D. Dal-Secco, J. A. Paron, S. H. P. de Oliveira, S. H. Ferreira, J. S. Silva, and F. Q. Cunha, “Neutrophil migration in inflammation: nitric oxide inhibits rolling, adhesion and induces apoptosis,” Nitric Oxide: Biology and Chemistry, vol. 9, no. 3, pp. 153–164, 2003. View at: Publisher Site | Google Scholar
  27. F. L. Lanza, “Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents,” The American Journal of Medicine, vol. 77, no. 1, pp. 19–24, 1984. View at: Publisher Site | Google Scholar
  28. K. Takeuchi, “Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility,” World Journal of Gastroenterology, vol. 18, no. 18, pp. 2147–2160, 2012. View at: Publisher Site | Google Scholar
  29. T. Brzozowski, P. C. Konturek, S. J. Konturek, I. Brzozowska, and T. Pawlik, “Role of prostaglandins in gastroprotection and gastric adaptation,” Journal of Physiology and Pharmacology, vol. 56, supplement 5, pp. 33–55, 2005. View at: Google Scholar
  30. M. L. Schubert, “Gastric secretion,” Current Opinion in Gastroenterology, vol. 27, no. 6, pp. 536–542, 2011. View at: Publisher Site | Google Scholar
  31. R. la Corte, M. Caselli, G. Castellino, G. Bajocchi, and F. Trotta, “Prophylaxis and treatment of NSAID-induced gastroduodenal disorders,” Drug Safety, vol. 20, no. 6, pp. 527–543, 1999. View at: Publisher Site | Google Scholar

Copyright © 2015 Jerônimo Aparecido Ribeiro-Junior et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views1110
Downloads536
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.